Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses
William J. Murphy(University of California Davis Medical Center), Robert H. Wiltrout(Frederick National Laboratory for Cancer Research), Naoko Seki(Kurume University), Jeff Subleski(Frederick National Laboratory for Cancer Research), Jon M. Wigginton(Johns Hopkins University), Bruce R. Blazar(University of Minnesota Medical Center), Anatoli Malyguine(Science Applications International Corporation (United States)), Susan E. Wilson(Eureka Therapeutics (United States)), Timothy Back(Science Applications International Corporation (United States)), Thomas J. Sayers(Science Applications International Corporation (United States)), Julie A. Hixon(Frederick National Laboratory for Cancer Research)
Cited by 98
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k